Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Ventilation 80% ICU admission 51% 7-point scale 87% primary 7-point scale (b) 80% Hospitalization time -15% c19colchicine.com Pascual-Figal et al. NCT04350320 Colchicine RCT LATE Favors colchicine Favors control
Pascual-Figal, 103 patient colchicine late treatment RCT: 80% lower mortality [p=0.24], 80% lower ventilation [p=0.24], 87% improved 7-point scale results [p=0.03], and 15% longer hospitalization [p=0.34] https://c19p.org/pascualfigal
copied to clipboard
Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
Pascual-Figal et al., International Journal of General Medicine, doi:10.2147/IJGM.S329810
11 Sep 2021    Source   PDF   Share   Tweet
RCT with 52 colchicine patients and 51 control patients, showing lower risk of clinical deterioration with treatment. COL-COVID. NCT04350320.
risk of death, 80.2% lower, RR 0.20, p = 0.24, treatment 0 of 52 (0.0%), control 2 of 51 (3.9%), NNT 26, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 80.2% lower, RR 0.20, p = 0.24, treatment 0 of 52 (0.0%), control 2 of 51 (3.9%), NNT 26, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 51.0% lower, RR 0.49, p = 0.44, treatment 2 of 52 (3.8%), control 4 of 51 (7.8%), NNT 25.
risk of 7-point scale, 87.5% lower, RR 0.13, p = 0.03, treatment 3 of 52 (5.8%), control 7 of 51 (13.7%), adjusted per study, odds ratio converted to relative risk, deterioration ≥1 point, multivariable, primary outcome.
risk of 7-point scale, 80.2% lower, RR 0.20, p = 0.24, treatment 0 of 52 (0.0%), control 2 of 51 (3.9%), NNT 26, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), deterioration ≥2 points.
hospitalization time, 14.6% higher, relative time 1.15, p = 0.34, treatment 52, control 51.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pascual-Figal et al., 9/11/2021, Randomized Controlled Trial, Spain, Europe, peer-reviewed, 14 authors, study period 30 April, 2020 - 4 December, 2020, trial NCT04350320.
All Studies   Meta Analysis
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit